Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2011 Jun 7.
Published in final edited form as: Tetrahedron Lett. 2011 Apr 27;52(17):2195–2198. doi: 10.1016/j.tetlet.2010.11.164

Aza-Nazarov cyclization cascades

Kiran Kumar Solingapuram Sai 1, Matthew J O'Connor 1, Douglas A Klumpp 1,*
PMCID: PMC3109674  NIHMSID: NIHMS294192  PMID: 21660198

Abstract

Benzamides with tethered acetal groups undergo reactions in CF3SO3H to give ring-fused isoindolinones by a cyclization cascade. The reaction initially forms an N-acyliminium ion which then gives the isoindolinone by the aza-Nazarov reaction. An unusual variant also cyclizes at the allylic position.

Keywords: Heterocycles, Aza-Nazarov, Superacid, N-Acyliminum ions, Cyclization


The Nazarov reaction is an acid-catalyzed cyclization involving the divinyl ketones and related compounds.1 This reaction has been useful in carbocyclic synthesis, including utilization in natural products and pharmaceutical agent syntheses. The mechanism of this conversion generally involves a concerted, 4π-electron electrocyclization. Recently, there have been several reports of aza-Nazarov reactions in which the nitrogen atoms have been incorporated into the new ring.2 Our own studies showed that N-acyliminium ions may undergo cyclization in the presence of superacidic CF3SO3H to give nitrogen heterocycles (Eq. 1).2d We proposed the involvement of superelectrophilic, dicationic species in these conversions. In these studies, the requisite N-acyliminium ions were prepared by the direct acylation of imines using carboxylic acid chlorides.

graphic file with name nihms294192e1.jpg (1)

The products from our reactions were derivatives of isoindolinones. This class of compounds is well known for a variety of biological activities. The 5-HT2c agonist (1),3 urotensin-II receptor antagonist (2),4 and HIV-1 integrase inhibitor (3)5 are representative examples of the biologically active isoindolinones (Scheme 1).

Scheme 1.

Scheme 1

N-Acyliminium ions may be generated by a number of methods.6 For example, King and coworkers prepared pyrrolo-tetrahydroiso-quinolinones via N-acyliminium ions by the acid-catalyzed reactions of phenylacetamides having tethered acetal groups.7 Another recent report described an N-acyliminium ion cyclization cascade done with a ketoamide.8 In the following Letter, we report a new route to the ring-fused aza-Nazarov products. This chemistry utilizes acid-promoted reactions of acetals, aldehydes and enamides to generate the intermediate N-acyliminium ions. Subsequent cyclizations then give the ring-fused aza-Nazarov products.

Our studies began with the syntheses of a series of acetal derivatives (49, Table 1). The compounds were prepared from the corresponding carboxylic acid chlorides and 4,4-diethoxy-1-butanamine. In reactions with CF3SO3H, the heterocyclic products were obtained in fair to good yields (entries 1–4). In an effort to cyclize into olefinic sites, indene and dihydronaphthalene derivatives (89) were also reacted in superacid. However, products (1920) were obtained from cyclization at the methyl carbon. We also explored the option of cyclizing alcohol substrates (entries 7–11). These substrates were prepared from the 5-amino-1-pentanol and the respective acid chlorides. The conversions were accomplished by initially oxidizing the alcohol substrates with PCC. In all cases, the intermediate enamides (2630) were formed and could be isolated. For example, substrate 12 gives the enamide 26 by reaction with PCC (Eq. 2). Further reaction with CF3SO3H gives the aza-Nazarov cyclization products (2125). In some cases, demethylation of the ether groups was also observed in the major product (entries 8 and 11). With compound 4, demethylation of the para-methoxy group also occurs (similar to compound 22), but it is a minor side reaction. Demethylation could be suppressed by carrying out the reaction with short reaction time. For the naphthyl systems (13 and 14), two types of cyclization were observed. Compound 13 favored the cyclization to form the six-member heterocyclic ring (24), while compound 14 reacted to give the aza-Nazarov product (25).

Table 1. Products and yields from cyclization cascades.

Entry Substrate Product Yield (%)
(1) graphic file with name nihms294192t1.jpg graphic file with name nihms294192t2.jpg 69
(2) graphic file with name nihms294192t3.jpg graphic file with name nihms294192t4.jpg 76
(3) graphic file with name nihms294192t5.jpg graphic file with name nihms294192t6.jpg 71
(4) graphic file with name nihms294192t7.jpg graphic file with name nihms294192t8.jpg 66
(5) graphic file with name nihms294192t9.jpg graphic file with name nihms294192t10.jpg 63
(6) graphic file with name nihms294192t11.jpg graphic file with name nihms294192t12.jpg 64
(7) graphic file with name nihms294192t13.jpg graphic file with name nihms294192t14.jpg 40c
(8) graphic file with name nihms294192t15.jpg graphic file with name nihms294192t16.jpg 43
(9) graphic file with name nihms294192t17.jpg graphic file with name nihms294192t18.jpg 81
(10) graphic file with name nihms294192t19.jpg graphic file with name nihms294192t20.jpg 53
(11) graphic file with name nihms294192t21.jpg graphic file with name nihms294192t22.jpg 45
a

Product from CF3SO3H.

b

Product from PCC oxidation, followed by reaction with CF3SO3H.

c

Isolated yields, calculated from conversions of enamides to final products.

graphic file with name nihms294192e2.jpg (2)

Although the conversions have not been fully optimized, reaction of compound 5 with 25 equiv of CF3SO3H gives a complete conversion to the heterocyclic product (16) in just 15 min (isolated yield 76%). Decreasing amounts of CF3SO3H give successively lower yields of product. With 1.0 equiv of acid, product 16 is formed in just 26% yield. Compounds 3132 did not give the expected aza-Nazarov cyclization products, but the corresponding enamides 3334 are major products from reactions in superacid (Eqs. 3 and 4).

graphic file with name nihms294192e3.jpg (3)
graphic file with name nihms294192e4.jpg (4)

The cyclizations of the acetal derivatives (47) occur through the formed N-acyliminium ions (Eq. 5). In the case of 5, ionization of the acetal leads to cyclization at the amide nitrogen and formation of compound 35. Further ionization leads to the N-acyliminium ion 36, where protosolvation can then lead to the superelectrophile (37). As shown in our previous report,2d formation of the superelectrophile (i.e., 37) significantly lowers the transition state energy barrier leading to the aza-Nazarov product. It is also expected that partial protonation of the carbonyl group could help facilitate the aza-Nazarov cyclization. Analysis of some product mixtures indicated the presence of minor amounts of enamides. These are likely formed during the reaction workup from unreacted N-acyliminium ion. In the reactions of alcohol substrates 1014, oxidation to the aldehydes leads to the formation of the enamide-type products (i.e., 26). Upon reaction of the superacid, the enamides are protonated and give the N-acyliminium ions. The resulting N-acyliminium ions then undergo the aza-Nazarov cyclization.

graphic file with name nihms294192e5.jpg (5)

The reactions of compounds 8 and 9 are quite unusual, giving products from reaction at the methyl group. It is proposed that these conversions are the result of equilibria between the N-acyliminium ion and an enol tautomer (Eq. 6). For example, compound 8 reacts in the superacid to give the N-acyliminium ion (38). Further reaction with the CF3SO3H gives the superelectrophile 39 which then gives the enol-type structure 40. This leads to product formation, either through a concerted 6π-electron electrocyclization or a stepwise electrophilic reaction. DFT calculations at the B3LYP 6-311G (d,p) level estimate the energy of structure 40 to be about 20 kcal/mol above the N-acyliminium ion 38 (Fig. 1).9 This energy difference is similar to other keto-enol tautomeric structures.10 Regarding the role of the superelectrophile (39), it has been shown in several recent studies that formation of superelectrophiles can greatly enhance the acidities of adjacent carbon–hydrogen bonds.11 Thus, formation of the superelectrophile may lead to a relatively low energy barrier between ions 38 and 40.

Figure 1.

Figure 1

Relative energies of ions 38 and 40.

graphic file with name nihms294192e6.jpg (6)

In summary, the conversions described above demonstrate that aza-Nazarov products may be prepared by superacid-promoted reactions involving amides with tethered acetal and aldehyde groups (which convert into enamides).12,13 These aza-Nazarov reactions are shown to produce ring-fused isoindolone derivatives. This represents a convenient route to a class of compounds known to possess a broad spectrum of biological activities.12

Supplementary Material

data

Acknowledgments

We gratefully acknowledge the support of the National Science Foundation (CHE-0749907) and the NIH–National Institutes of General Medical Sciences (GM085736-01A1). We also thank Ms. Anila Kethe for assistance in preparing this manuscript.

References and notes

  • 1.For recent reviews, see: Nakansihi W, West FG. Curr Opin Drug Discov Dev. 2009;12:732.Tius MA. Eur J Org Chem. 2005:2193.Pellisser H. Tetrahedron. 2005;61:6479.Frontier AJ, Collison C. Tetrahedron. 2005;61:7577.
  • 2.(a) Shimada N, Ashburn BO, Basak AK, Bow WF, Vicic DA, Tius MA. Chem Commun. 2010;46:3774. doi: 10.1039/b927564a. [DOI] [PubMed] [Google Scholar]; (b) Ghavtadze N, Froehlich R, Bergander K, Wuerthwein EU. Synthesis. 2008;21:3397. [Google Scholar]; (c) Ghavtadze N, Froehlich R, Wuerthwein EU. Eur J Org Chem. 2008:3656. doi: 10.1021/jo900270e. [DOI] [PubMed] [Google Scholar]; (d) Klumpp DA, Zhang Y, O'Connor MJ, Esteves PM, de Almeida LS. Org Lett. 2007;9:3085. doi: 10.1021/ol0711570. [DOI] [PubMed] [Google Scholar]; (e) Dieker J, Froehlich R, Wuerthwein EU. Eur J Org Chem. 2006:5339. [Google Scholar]
  • 3.Wacker DA, Varnes JG, Malmstrom SE, Cao X, Hung CP, Ung T, Wu G, Zhang G, Zuvich E, Thomas MA, Keim WJ, Cullen MJ, Rohrbach KW, Qu Q, Narayanan R, Rossi K, Janovitz E, Lehman-McKeeman L, Malley MF, Devenny J, Pelleymounter MA, Miller KJ, Robl JA. J Med Chem. 2007;50:1365. doi: 10.1021/jm0612968. [DOI] [PubMed] [Google Scholar]
  • 4.Luci DK, Lawson EC, Ghosh S, Kinney WA, Smith CE, Qi J, Wang Y, Minor LK, Maryanoff BE. Tetrahedron Lett. 2009;50:4948. [Google Scholar]
  • 5.Zhao XZ, Maddali K, Marchand C, Pommier Y, Burke TR., Jr Bioorg Med Chem. 2009;17:5318. doi: 10.1016/j.bmc.2009.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Maryanoff BE, Zhang HC, Cohen JH, Turchi IJ, Maryanoff CA. Chem Rev. 2004;104:1431. doi: 10.1021/cr0306182. [DOI] [PubMed] [Google Scholar]
  • 7.(a) Wu L, Aliev AE, Caddick S, Fitzmaurice RJ, Tocher DA, King FD. Chem Commun. 2010;46:318. doi: 10.1039/b919114c. [DOI] [PubMed] [Google Scholar]; (b) King FD, Aliev AE, Caddick S, Copley RCB. Org Biomol Chem. 2009;7:3561. doi: 10.1039/b907400g. [DOI] [PubMed] [Google Scholar]; (c) King FD, Aliev AE, Caddick S, Tocher DA, Courtier-Murias D. Org Biomol Chem. 2009;7:167. doi: 10.1039/b815195d. [DOI] [PubMed] [Google Scholar]
  • 8.Muratore ME, Holloway CA, Pilling AW, Storer RI, Trevitt G, Dixon DJ. J Am Chem Soc. 2009;131:10796. doi: 10.1021/ja9024885. [DOI] [PubMed] [Google Scholar]
  • 9.Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA, Jr, Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople JA. Calculations done using Gaussian 03, Revision C.02. Gaussian, Inc.; Wallingford, CT: 2004. [Google Scholar]
  • 10.Yamataka H, Rappoport Z. J Am Chem Soc. 2000;122:9818. [Google Scholar]
  • 11.Olah GA, Klumpp GA. Superelectrophiles and their Chemistry. Wiley & Sons; New York: 2008. pp. 126–127. [Google Scholar]
  • 12.Typical synthetic procedure: The 4-aminobutyraldehyde diethyl acetal (1.0 mmol) was dissolved in 10 mL of dry dichloromethane, followed by the addition of 2.0 equiv of NEt3 at 0 °C. To this cold reaction mixture, the acid chloride (1.1 equiv dissolved in 4 mL of dry dichloromethane) was slowly added through an addition funnel. The reaction mixture was stirred for 4 h at 25 °C and then quenched using 10 g of ice. The solution was extracted twice with dichloromethane, washed twice with saturated NH4Cl, thrice with brine solution, and then dried over anhydrous sodium sulfate. The tethered acetals were isolated by column chromatography and characterized by NMR analysis. The tethered acetal (49, 0.4 mmol) or the enamide (from alcohols 1014, 0.4 mmol) is dissolved in 2 mL of CHCl3 to which is added triflic acid (2 mL, 22 mmol). The mixture is stirred for 5 h at 25 °C and then poured over 10 g of ice. The solution is extracted with chloroform (3 × 20 mL) and the organic solution is washed successively with water and brine. The solution is dried (Na2SO4) and the product is isolated using column chromatography (hexanes/Et2O).
  • 13.Analytical data: Compound 15, mp 119–122 °C; 1H NMR (500 MHz, CDCl3) δ: 7.08 (s, 1H), 4.64 (q, 1H, J = 5 Hz), 3.96 (s, 3H), 3.94 (s, 3H), 3.92 (s, 3H), 3.66 (q, 1H, J = 8 Hz), 3.39 (t, 1H, J = 9 Hz), 2.39–2.30 (mult, 3H), 1.26–1.15 (mult, 1H); 13C NMR (500 MHz, CDCl3) δ: 171.4, 155.2, 148.4, 144.1, 143.6, 131.8, 129.0, 102.0, 62.6, 61.0, 56.3, 41.8, 29.8, 29.6. Low-resolution mass spectra, EI: 263 (M+), 235, 220, 192. Compound 16, mp 141 – 143 °C; 1H NMR (500 MHz, CDCl3) δ: 6.88 (s, 1H), 6.57 (s, 1H), 4.60 (q, 1H, J = 5 Hz), 3.85 (s, 3H), 3.83 (s, 3H), 3.66 (q, 1H, J = 8 Hz), 3.40 (t, 1H, J = 7 Hz), 2.37–2.29 (mult, 3H), 1.18–1.14 (mult, 1H); 13C NMR (500 MHz, CDCl3) δ: 171.6, 161.9, 155.5, 135.9, 127.6, 102.5, 97.9, 62.7, 55.8, 55.5, 41.7, 29.7, 29.4; Low-resolution mass spectra, EI: 233 (M+), 205, 190, 162. Compound 17, mp 141–143 °C. 1H NMR (500 MHz, CDCl3) δ: 6.88 (s, 1H), 6.57 (s, 1H), 4.60 (q, 1H, J = 5 Hz), 3.85 (s, 3H), 3.83 (s, 3H), 3.66 (q, 1H, J = 8 Hz), 3.40 (t, 1H, J = 7 Hz), 2.37–2.29 (mult, 3H), 1.18–1.14 (mult, 1H); 13C NMR (500 MHz, CDCl3) δ: 171.6, 161.9, 155.5, 135.9, 127.6, 102.5, 97.9, 62.7, 55.8, 55.5, 41.7, 29.7, 29.4; Low-resolution mass spectra, EI: 233 (M+), 205, 190, 162. Compound 18, mp 120–123 °C. 1H NMR (500 MHz, CDCl3) δ: 7.28 (d, 1H, J = 8 Hz), 7.20 (s, 1H), 7.02 (d, 1H, J = 8 Hz), 4.56 (q, 1H, J = 5 Hz), 3.75 (s, 3H), 3.64 (q, 1H, J = 8 Hz), 3.35 (t, 1H, J = 6 Hz), 2.32–2.19 (mult, 3H), 1.20–1.11 (mult, 1H); 13C NMR (500 MHz, CDCl3) δ: 171.6, 160.1, 138.7, 134.9, 123.4, 119.7, 106.7, 64.2, 55.5, 41.9, 29.6, 29.2; Low-resolution mass spectra, EI: 203 (M+), 175, 147, 132. Compound 19, mp 104–106 °C; 1H NMR (500 MHz, CDCl3) δ: 7.43 (d, 1H, J = 7 Hz), 7.40–7.35 (mult, 1H), 7.36–7.29 (mult, 2H), 3.94–3.92 (mult, 1H), 3.78–3.72 (mult, 2H), 3.63–3.56 (mult, 2H), 3.06 (dd, 1H, J = 12 Hz), 2.54–2.46 (mult, 1H), 2.34–2.29 (mult, 1H), 2.11–2.07 (mult, 1H), 1.89–1.85 (mult, 1H), 1.83–1.77 (mult, 1H); 13C NMR (500 MHz, CDCl3) δ: 163.2, 148.6, 145.1, 142.3, 135.7, 127.2, 126.6, 124.6, 120.4, 58.2, 43.8, 35.7, 33.4, 29.6, 23.4; Low-resolution mass spectra, EI: 225 (M+), 156, 128, 70. Compound 20, 1H NMR (300 MHz): δ 1.70–1.95 (m, 2H), 2.05–2.15 (m, 1H), 2.27–2.36 (m, 1H), 2.41–257 (m, 2H), 2.67–2.97 (m, 4H), 3.51–3.62 (m, 1H), 3.67–3.85 (m, 2H), 7.20–7.32 (m, 4H); 13C NMR (DEPT results in parentheses; 300 MHz, CDCl3): δ 21.6 (CH2), 23.1 (CH2), 28.0 (CH2), 31.1 (CH2), 33.7 (CH2), 44.4 (CH2), 55.9 (CH), 123.3 (CH), 126.5 (CH), 127.8 (CH), 128.6 (CH), 129.1 (C), 133.8 (C), 137.5 (C), 138.6 (C), 164.6 (C); Low-resolution mass spectrum, EI: 239 [M+ ], 238, 170, 141, 115. HRMS C16 H16ON (M–H) calcd, 238.12319, found 238.12258. Compound 21, MP 119–124 °C; 1H NMR (300 MHz, CDCl3): δ 1.44–1.57 (m, 1H), 1.62.1.78 (m, 2H), 1.81–1.90 (m, 1H), 1.98–2.08 (m, 1H), 2.53–2.59 (m, 1H), 3.00–3.10 (m, 1H), 4.43–4.50 (m, 2H), 7.42–7.48 (m, 2H); 13 C NMR (300 MHz, CDCl3): δ 23.4, 25.8, 31.8, 40.3, 58.2, 122.2, 124.5, 125.0, 126.0, 132.4, 146.1, 150.2, 162.9; Low-resolution mass spectrum, EI: 243 [M+ ], 214, 186, 160. HRMS C14H13ONS calcd, 243.07179, found 243.07083. Compound 22, mp 171–179°C; 1H NMR (500 MHz, CDCl3) δ, 1.07 (m, 1H), 1.36–1.44 (m, 1H), 1.64–1.67 (m, 1H), 1.75–1.84 (m, 1H), 1.92–2.03 (m, 1H), 2.51–2.58 (m, 1H), 2.96 (dt, J = 13, 3.5 Hz, 1H), 3.93 (s, 3H), 3.98 (s, 3H), 4.28–4.32 (m, 1H), 4.43–4.46 (m, 1H), 7.14 (s, 1H); 13C NMR (500 MHz, CDCl3) δ, 23.7, 25.4, 31.4, 39.9, 56.6, 57.7, 60.4, 100.9, 123.7, 131.3, 141.3, 141.8, 148.5, 166.2; Low-resolution mass spectrum, EI: 263 [M+ ], 262, 232, 206, 165. HRMS C14H17O4N calcd, 263.11576, found 263.11501. Compound 23, mp 121–124 °C. 1H NMR (500 MHz, CDCl3) δ, 6.71 (s, 1H), 6.33 (s, 1H), 4.24 (d, 1H, J = 10 Hz), 3.99 (d, 1H, J = 10 Hz), 3.63 (s, 3H), 3.59 (s, 3H), 2.75 (t, 1H, J = 10 Hz), 2.36 (d, 1H, J = 10 Hz), 1.73 (d, 1H, J = 12 Hz), 1.59 (d, 1H, J = 12 Hz), 1.42 (q, 1H, J = 13 Hz), 1.15 (q, 1H, J = 10 Hz), 0.78 (q, 1H, J = 10 Hz); 13C NMR (500 MHz, CDCl3) δ, 165.6, 161.4, 155.3, 134.6, 126.3, 101.7, 97.9, 57.4, 55.5, 55.1, 39.5, 30.9, 25.4, 23.3; Low-resolution mass spectra (EI): 247 (M+), 216, 191, 114. Compound 24 1H NMR (300 MHz, CDCl3): δ, 1.58–1.72 (m, 2H), 1.72–1.86 (m, 2H), 1.93–2.14 (m, 2H), 2.71 (dt, J = 12.6, 2.7 Hz, 1H), 4.84 (d, J = 11.7 Hz, 1H), 5.07–5.12 (m, 1H), 7.30 (d, J = 7.2 Hz, 1H), 7.45–7.59 (m, 2H), 7.74–7.77 (d, J = 8.4 Hz, 1H), 7.91–7.94 (m, 1H), 8.35 (dd, J = 7.2, 0.9 Hz, 1H); 13 C NMR (300 MHz, CDCl3): δ, 25.6, 25.9, 39.2, 44.0, 61.2, 122.8, 124.3, 126.0, 126.1, 126.3, 126.3, 127.3, 131.2, 132.4, 133.0, 161.4; Low-resolution mass spectrum, EI: 237 [M+ ], 236, 208, 182, 153. HRMS C16H15ON calcd, 237.11537, found 237.11414. Compound 25, mp 149–151 °C; 1H NMR (500 MHz, CDCl3): δ, 1.54–1.61 (m, 1H), 1.84–1.92 (m, 2H), 1.97–2.20 (m, 1H), 2.28–2.34 (m, 1H), 2.87 (dt, J = 13.5, 4.0 Hz, 1H), 3.95–3.98 (m, 1H), 4.61–4.64 (m, 1H), 5.30 (dd, J = 10, 4 Hz, 1H), 7.30 (s, 1H), 7.40–7.43 (m, 1H), 7.52–7.55 (m, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 8.5, 1H), 8.57 (s, 1H); 13C NMR (500 MHz, CDCl3): δ, 21.4, 23.7, 31.7, 41.6, 85.9, 111.4, 118.2,124.8, 126.7, 128.5, 129.2, 129.5, 129.8, 136.6, 152.7, 163.1; Low-resolution mass spectrum, EI: 253 [M+ ], 170, 142, 114, 83. HRMS C16H15O2N calcd, 253.11028, found 253.10933. Compound 26, mp 166–169 °C. 1 H NMR (500 MHz, CDCl3) δ: 7.00 (s, 1H), 4.61 (q, 1H, J = 10 Hz), 3.89 (s, 3H), 3.79 (s, 3H), 3.56 (q, 1H, J = 8 Hz), 3.31 (t, 1H, J = 9 Hz), 2.32–2.22 (mult, 3H), 1.19–1.12 (mult, 1H); 13C NMR (500 MHz, CDCl3) δ: 172.0, 149.0, 141.9, 132.2, 124.4, 62.7, 60.3, 56.5, 41.8, 29.8, 29.5, 29.1; Low-resolution mass spectra, EI: 249 (M+), 221, 206, 178.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

data

RESOURCES